Compare Recursion Pharmaceuticals Inc (RXRX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Weibo Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Weibo Corp trades at $8 (market cap $1.95B). The key difference: Weibo Corp is the larger of the two by market cap, and Weibo Corp pays a 7.63% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WB | |
|---|---|---|
Market Cap | $1.53B | $1.95B |
Sector | Health | Media |
52-Week High | $6.79 | $12.83 |
52-Week Low | $2.84 | $7.20 |
Enterprise Value | $946.50M | $1.22B |
Dividend Yield | — | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Weibo (WB) trades at $8.00, up 3.23% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 21.15% net income margin and trades at discounted valuations including a P/E of 5.59 and P/B of 0.51. Recent earnings missed expectations for three consecutive quarters, but the company maintains robust cash flow generation and a solid balance sheet with $2.35 billion in cash.
The outlook is mixed: deep value metrics and analyst buy ratings (45%) support upside potential, but competitive pressures and recent earnings misses pose risks. The stock's 8% dividend yield provides income support while investors await improved execution and AI monetization opportunities to drive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
